Titre du document / Document title

Relative potency of fexofenadine HCl 180 mg, loratadine 10 mg, and placebo using a skin test model of wheal-and-flare suppression

Auteur(s) / Author(s)

KALINER Michael A. ⁽¹⁾ ; WHITE Martha V. ⁽¹⁾ ; ECONOMIDES Athena ⁽¹⁾ ; CRISALIDA Tera ⁽¹⁾ ; HALE Mary ⁽¹⁾ ; YUNING LIAO ⁽²⁾ ; CHRISTIAN Claire D. ⁽²⁾ ; GEORGES George C. ⁽²⁾ ; WOODWORTH Thomas H. ⁽²⁾ ; MEEVES Suzanne G. ⁽²⁾ ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

⁽¹⁾ The Institute for Asthma and Allergy, Chevy Chase, Maryland, ETATS-UNIS
⁽²⁾ Aventis Pharmaceuticals, Bridgewater, New Jersey, ETATS-UNIS

Résumé / Abstract

Background: H₁-receptor antagonists differ in their ability to produce peripheral H₁-blockade. Suppression of histamine-induced flares and wheals is a useful objective test for measuring these differences. Objective: To evaluate the relative potency of fexofenadine HCl 180 mg, loratadine 10 mg, and placebo (PBO) in suppressing histamine-induced flares and wheals and compare the onset, duration, and maximum suppression of histamine achieved with each agent. Methods: Thirty healthy volunteers were enrolled in this randomized, double-blind, single-dose, crossover study. Flares and wheals induced by skin-prick testing with histamine 1.8 mg/mL were measured before treatment, every 20 minutes during the first hour after dosing, and thereafter hourly between 2 and 12 hours and between 23 and 25 hours postdose. Results: Fexofenadine was significantly more effective than loratadine in suppressing the histamine-induced flare response at hours 2 through 7 and 10 through 12 and produced greater flare suppression than did PBO at hours 2 through 25. Onset of flare suppression occurred 2 hours after dosing with fexofenadine and 4 hours after dosing with loratadine. Likewise, fexofenadine was superior to loratadine in suppressing the wheal response from hours 1 through 12 and was more effective than PBO at hours 1 through 12, 24, and 25. Throughout the 25-hour measurement interval, the magnitude of difference in both wheal and flare suppression consistently favored fexofenadine over loratadine. Conclusions: In a skin test model of wheal-and-flare suppression, fexofenadine showed rapid distribution into the skin compartment with faster onset of action and greater potency vs loratadine.

Revue / Journal Title

Annals of allergy, asthma, & immunology   ISSN 1081-1206 

Source / Source

2003, vol. 90, n^o6, pp. 629-634 [6 page(s) (article)] (16 ref.)

Langue / Language

Anglais

Editeur / Publisher

American College of Allergy, Asthma, & Immunology, McLean, VA, ETATS-UNIS  (1995) (Revue)

Mots-clés anglais / English Keywords

Secondary effect ; Skin test ; Models ; H1 Histamine receptor ; Loratadine ; Antagonist ; Antihistaminic ; Fexofenadine ; Comparative study ; Human ; Pharmacology ;

Mots-clés français / French Keywords

Effet secondaire ; Test cutané ; Modèle ; Récepteur histaminergique H1 ; Loratadine ; Antagoniste ; Antihistaminique ; Fexofénadine ; Etude comparative ; Homme ; Pharmacologie ;

Mots-clés espagnols / Spanish Keywords

Efecto secundario ; Prueba cutáneo ; Modelo ; Receptor histaminérgico H1 ; Loratadina ; Antagonista ; Antihistamínico ; Fexofenadina ; Estudio comparativo ; Hombre ; Farmacología ;

Localisation / Location

INIST-CNRS, Cote INIST : 5910, 35400011846665.0100